Zacks Investment Research downgraded GenVec Inc (NASDAQ:GNVC) to Hold in a report released today.
- Updated: September 26, 2016
Yesterday GenVec Inc (NASDAQ:GNVC) traded -1.87% lower at $0.49. The company’s 50-day moving average is $0.58 and its 200-day moving average is $0.66. The last closing price is down -24.93% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 30,566 shares of the stock were exchanged, down from an average trading volume of 123,328
Zacks Investment Research has downgraded GenVec Inc (NASDAQ:GNVC) to Hold in a report released on 9/26/2016.
Previously on 6/20/2016, Rodman & Renshaw reported on GenVec Inc (NASDAQ:GNVC) raised the target price from $0.00 to $2.30. At the time, this indicated a possible upside of 2.71%.
See Chart Below
GenVec Inc has a 52 week low of $0.35 and a 52 week high of $3.69 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 1 broker has issued a report on the stock. The consensus target price is $5.00 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About GenVec Inc (NASDAQ:GNVC)
GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.